Ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3D fluid-attenuated inversion recovery

Ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3D fluid-attenuated inversion recovery

Ipilimumab, a human monoclonal antibody against cytotoxic T-lymphocyte antigen 4, was approved by the U.S. FDA (Food and Drug Administration) in 2011 for the treatment of unresectable or metastatic malignant melanoma. Occurrence of hypophysitis, an immune-related adverse event due to ipilimumab use,...

Full description

Bibliographic Details
Main Authors: Fumine Tanaka, MD, Ryota Kogue, MD, Masayuki Maeda, MD, PhD, Maki Umino, MD, PhD, Yasuo Nakai, MD, Atsuro Takeshita, MD, Hajime Sakuma, MD, PhD
Format: Article
Language:English
Published: Elsevier 2018-02-01
Series:Radiology Case Reports
Subjects:
Ipilimumab
Hypophysitis
Optic tract
3D FLAIR
Melanoma
Online Access:http://www.sciencedirect.com/science/article/pii/S1930043317304442

Similar Items

Similar Items